Overview
In the Driver’s Seat with Multiple Sclerosis: Optimizing DMT Selection
Optimizing DMT Selection in MS
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
How do you navigate the growing number of treatments for multiple sclerosis? What is the best approach for treatment naïve MS patients? When is the best time to initiate high-efficacy DMTs? This multifaceted patient-focused activity addresses those burning questions and provides an interactive customized learning experience to address the many challenges of MS care. Navigate through a decision tree in a step-by-step matrix with supportive educational context and clinical commentary from expert faculty. In addition, cases will sharpen decision-making skills to meet the treatment needs of diverse patients and discuss the variations of treatment options for women and men.
This educational activity is designed for neurologists, neurology APPs, and other MS providers who care for and manage patients with multiple sclerosis.
Multiple sclerosis (MS) can be a devastating diagnosis to receive as a patient. Although an expanding armamentarium of disease modifying therapies (DMTs) offers hope for delaying the progression of this debilitating disease, MS still affects patients’ daily lives extensively and patients with MS still require a great deal of professional support monitoring symptoms, evaluating medication changes, managing physical limitations, and addressing the disease’s psychosocial implications. However, with the sheer number of DMTs available for the treatment of MS, clinicians caring for these patients of all practice levels require ongoing education on appropriate DMT selection. This learning tree and case challenge activity will help the clinician choose the right therapy for an individual patient, and decide when to switch or consider stopping DMTs to improve patient outcomes.
Upon completion of this activity, participants will be able to:
-Interpret the latest evidence and integrate it into clinical practice
-Introduce strategies to identify patients who will benefit from specific therapies
-Apply evidence-based strategies for DMT selection and monitoring treatment response to optimize personalized management in patients with MS.
-Interpret the latest evidence and integrate it into clinical practice
-Introduce strategies to identify patients who will benefit from specific therapies
-Apply evidence-based strategies for DMT selection and monitoring treatment response to optimize personalized management in patients with MS.
Sponsored by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by independent educational grants from Biogen and Novartis Pharmaceuticals, Inc.
Riley Bove, MD, MSc
Associate Professor
Weill Institute for Neurosciences
University of California San Francisco
San Francisco, CA
Associate Professor
Weill Institute for Neurosciences
University of California San Francisco
San Francisco, CA
Darin T. Okuda, MD, FAAN, FANA
Professor of Neurology
Director, Neuroinnovation Program
Director, Multiple Sclerosis & Neuroimmunology Imaging Program
Director, Radiologically Isolated Syndrome Consortium
Department of Neurology
UT Southwestern Medical Center at Dallas
Dallas, TX
Rush University Medical Center and The Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
Riley Bove, MD, MSc (Faculty)
Research Grants: Biogen, Novartis, Roche, Genentech
Consultant Agreements: Alexion Pharmaceuticals, Biogen, EMD Serono, Horizons Therapeutics, Janssen Pharmaceuticals, Novartis, Sanofi Genzyme, TG Therapeutics
Darin T. Okuda, MD, FAAN, FANA (Faculty)
Research Grant: Novartis
Consultant Agreements: Alexion Pharmaceuticals, Celgene/Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen Pharmaceuticals, Novartis, Osmotica Pharmaceuticals, RVL Pharmaceuticals, Inc., TG Therapeutics, Viela Bio Inc.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Rituximab for treatment of PPMS and relapsing MS.
Rush University Medical Center and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Ty Jackson at tjackson@achlcme.org.
For questions, contact Ty Jackson at tjackson@achlcme.org.
This activity is being presented without bias and with commercial support.
Rush University Medical center designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring material for a maximum of 1.25 contact hours.
MIPS Improvement Activity
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
